Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis

HAYWARD, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the screening for the RESULT Phase 3 clinical study has surpassed the halfway...
September 06, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference

HAYWARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
September 05, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference

HAYWARD, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
August 28, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy

Trend toward preservation of renal function (eGFR) in blisibimod treated patientsLack of disease progression, as measured by proteinuria in blisibimod treated patients HAYWARD, Calif., Aug. 28, 2017...
August 14, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network

HAYWARD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due...
August 09, 2017 16:00 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy

HAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug...
August 09, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results

RESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study...
July 10, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network

HAYWARD, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due...
July 06, 2017 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura

Study is being conducted in the US, Europe, and IsraelTop line data expected end of 2017 or early 2018 HAYWARD, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Anthera (Nasdaq:ANTH) today announced that...
May 15, 2017 16:02 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura

Four-week non-inferiority, Coefficient of Fat Absorption (CFA) primary endpoint comparing Sollpura to Pancreaze in patients with exocrine pancreatic insufficiency due to cystic fibrosisStudy design...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right